Renal Cancer
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
November 15, 2022
NFE2L3 as a Potential Functional Gene Regulating Immune Microenvironment in Human Kidney Cancer.
November 14, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
November 14, 2022
Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study).
November 11, 2022
Kidney Tumors: New and Emerging Kidney Tumor Entities.
November 11, 2022
The incidence and risk factors of chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma.
November 8, 2022
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
November 7, 2022
A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma.
November 7, 2022
Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential VHL Mutations Underlie Multifocal ccRCC.
November 4, 2022
Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96).
November 4, 2022
Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.
November 3, 2022
The significance of CD14 in clear cell renal cell carcinoma progression and survival prognosis.
November 3, 2022